Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.

You may also be interested in...



Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs

Developing new drugs is only one of the four actions to prevent antibiotic resistance CDC calls for in a report that encourages “stewardship” of available therapies.

Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says

FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS005797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel